Benzinga | Jul 15, 2020 08:03AM EDT

Adamas Highlights Presentation Of New Post-Hoc Phase 3 Data Analysis For GOCOVRI Ini Parkinson's Disease At 2020 American Academy Of Neurology (AAN) Science Highlights Platform

EMERYVILLE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced its presentation of a new post-hoc pivotal trial data analysis at the American Academy of Neurology (AAN) Science Highlights Platform showing GOCOVRI decreasing dyskinesia and OFF time for people with Parkinson's Disease (PD) using GOCOVRI(r) (amantadine) extended release capsules. GOCOVRI is indicated for the treatment of dyskinesia in people with Parkinson's disease receiving levodopa-based therapy. The abstract and poster presentation are available on the 2020 AAN Science Highlights Platform.